Time to Excretion of Contrast, a Maastricht Prospective Observational Study

Acute Kidney Injury Clinical Trial

— TEMPOS  

Official title:

Time to Excretion of Contrast, a Maastricht Prospective Observational Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04603261
• Other study ID #: NL.MUMC.AMACINGrp.2
• Status: Withdrawn
• Start date: November 1, 2097
• Est. completion date: November 1, 2099

Study information

• Verified date: October 2023
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Risk of contrast-induced kidney injury is expected to be strongly correlated with exposure time. Studies on the excretion of iodinated contrast material are few and have mostly been carried out in patients with normal renal function. Although case wise reports of persistent renograms have been published, it is not known how long contrast is retained before excretion in patients with eGFR <30 mL/min/1.73m2, nor which of these patients are most susceptible to contrast retention. The current observational study aims to compare contrast elimination time and % contrast excretion in patients with eGFR <30 mL/min/1.73m2, to matched patients (for age, sex and contrast procedure type) with eGFR 30-59 and eGFR >=60 mL/min/1.73m2.

Description:

The primary aim of the current study is to determine contrast elimination time and % in three groups of patients, (with severely reduced, moderate, and mildly reduced to normal renal function). Secondary aims are to explore whether specific situations/characteristics result in higher probability of delayed elimination of contrast, and whether there is a link between elimination time and adverse post-contrast outcomes (post-contrast incidences of acute kidney injury; post-contrast changes in eGFR within 5 days from baseline; 1-month post-contrast change in eGFR; 1-month post-contrast incidences of eGFR decline >=5 mL/min/1.73m2; 1-month dialysis and mortality).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 1, 2099
• Est. primary completion date: November 1, 2099
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+ For each included patient with eGFR <30 mL/min/1.73m2, two matched patients will be

included:

• 1. eGFR 30-59 mL/min/1.73m2 referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+ with age, sex and contrast procedure type matching the age, sex and contrast procedure type of an eGFR <30 mL/min/1.73m2 participant.
• 2. eGFR >=60 mL/min/1.73m2 referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+ with age, sex and contrast procedure type matching the age, sex and contrast procedure type of an eGFR <30 mL/min/1.73m2 participant.

Exclusion Criteria:

• age <18 years
• dialysis or pre-dialysis
• intravascular contrast administration having occurred <30 days before the first baseline sample
• emergency or intensive care status.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Contrast-induced Nephropathy
• Renal Insufficiency

Intervention

Diagnostic Test:
• Contrast concentration in urine
Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed. Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast.

Locations

Country	Name	City	State
Netherlands	Maastricht UMC	Maastricht

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time to contrast-free urine.	time to the first contrast-free urine sample from the time of intravascular iodinated contrast administration. Time to contrast-free urine will be compared between three groups of patients (with eGFR <30 mL/min/1.73m2, eGFR 30-59 mL/min/1.73m2, and eGFR >=60 mL/min/1.73m2).	5 days
Secondary	% contrast elimination.	percentage of total contrast administered excreted in urine within 5 days. Percentage contrast elimination will be compared between three groups of patients (with eGFR <30 mL/min/1.73m2, eGFR 30-59 mL/min/1.73m2, and eGFR >=60 mL/min/1.73m2).	5 days
Secondary	contrast elimination versus adverse post-contrast outcomes.	The underlying hypothesis is that delayed elimination increases contrast toxicity which increases adverse event risk. This will be explored by comparing percentages with post-contrast adverse events (acute kidney injury; changes in eGFR; eGFR decline =5mL/min/1.73m2; dialysis; mortality; up to 1-month) in groups with and without delayed elimination, stratified by eGFR (<30, 30-59, =60). Relevant patient and procedural characteristics will also be compared to identify potential predictors of delayed elimination.; Contrast elimination times are unknown, therefore 'delayed' is defined as time to contrast-free urine exceeding patient group median value. In clinical practice, normal contrast elimination is assumed to be =24h. Therefore, 1. Normal (=24h); 2. Delayed (24-48h); 3. Severely delayed (>48h) elimination subgroups will also be compared. Subgroup cut-off values may be added at a later stage (e.g., in the event of many or no patients with elimination >48h).	1 month